Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates [Yahoo! Finance]
Anebulo Pharmaceuticals, Inc. (ANEB)
Company Research
Source: Yahoo! Finance
developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three and twelve months ended June 30, 2025, and recent updates. Fourth Quarter Fiscal Year 2025 and Subsequent Highlights: On September 25, 2025, Anebulo announced the first subjects dosed in a Phase 1 single ascending dose ("SAD") study of an intravenous (IV) formulation of its lead drug candidate selonabant. Selonabant is under development for treatment of acute cannabis-induced toxicity in children. The study will investigate the safety, tolerability, and pharmacokinetics of selonabant administered intravenously in healthy adult subjects aged 18 to 25 years. The randomized, double-blind, placebo-controlled study design was cleared by the FDA and is being conducted at a single Phase 1 clinical study site in Austin, Texas. Anebulo has been awarded the second-year tranche ($994,300) of an ongoing collaborative grant fr
Show less
Read more
Impact Snapshot
Event Time:
ANEB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANEB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANEB alerts
High impacting Anebulo Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANEB
News
- We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
- Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent UpdatesBusiness Wire
- Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity [Yahoo! Finance]Yahoo! Finance
- Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced ToxicityBusiness Wire
- Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives [Yahoo! Finance]Yahoo! Finance
ANEB
Sec Filings
- 10/14/25 - Form SC
- 10/10/25 - Form PRER14A
- 9/29/25 - Form 10-K
- ANEB's page on the SEC website